Objective: Two recent studies in resectable non-small cell lung cancer by the Lung Cancer Study Group (LCSG) suggested an advantage to adjuvant therapy with cyclophosphamide, doxorubicin (Adriamycin), and cisplatin (CAP). Neither study had a no-treatment control arm. 
Objective: Two recent studies in resectable non-small cell lung cancer by the Lung Cancer Study Group (LCSG) suggested an advantage to adjuvant therapy with cyclophosphamide, doxorubicin (Adriamycin), and cisplatin (CAP). Neither study had a no-treatment control arm. The purpose of this study was Statistical Methods The trial size was determined by the number of patients necessary for 90 events to occur (power 0.9 to detect a twofold difference in median survival with a two-sided log rank test using a significance level of 0.05). The Pearson X2 test was used for contingency table analysis; Yates' continuity correction was used in the case of two-by-two tables.6 Survival and recurrence were estimated by the Kaplan-Meier method7 and two-sided significance tests were based on log rank statistics as given by Mantel8 but without continuity correction. Survival analysis stratification variables were used to adjust the data as were other important covariates by using the Cox model9 or by using stratified log rank score statistics. All end points were defined in the usual way starting on the day of randomization.
RESULTS
Patients were entered in the study from November 1980 to May 1986 and data for the analysis were collected until January 15, 1990 . No further update is planned. Among the 283 randomized patients, 14 had major protocol violations and were declared ineligible. Among the 269 eligible patients, 29 did not receive the assigned treatment. Therefore, there were 240 (85%) eligible treated patients. Among the eligible patients, 82% were male, 59% were at least 60 years old, 56% had nonsquamous histologic features, and 84% had tumors classified as T2N0, the remainder as TiN1. There were no statistically significant differences by treatment arm for the potential important prognostic variables that were not included in the stratification (weight loss >10%, neutrophil count >7,000/mm3, lobectomy, segmental resection vs pneumonectomy/wedge resection, sex, the presence or absence of heart disease prior to randomization, and complications following surgery).
Relapse and Survival
The mean time from random assignment of the 269 eligible patients was 6.4 years, with a mean follow-up of 3.8 years. One hundred one recurrences occurred along with 31 second primary tumors (all sites, not just lung) and 127 deaths at the time of analysis. We looked for individual potential prognostic variables. Only prior heart disease and a preoperative neutrophil count >7,000/mm3 were associated with significantly greater death rates. A number of other parameters were associated with higher recurrence rates.
The time to first recurrence, excluding second primary tumors, is shown in Figure 1 . The time to death from any cause is shown in Figure 2 . No treatment difference is observed even when adjustment occurred using the Cox model 
Treatment Compliance
Only 80% of the eligible patients received the initial dose of CAP, 86% of these receiving the treatment on time. Sixty-six percent of the eligible patients received at least two cycles of CAP (73% of these received at least the initial two cycles on time). Only 53% of the eligible patients received all four cycles of CAP (57% of these received all four cycles on time). Dose intensity analysis was not done.
Sites of First Recurrence
The sites of first recurrences are shown in Table 1 . Nonlocal recurrences predominate with isolated brain recurrences (26% of the total) equal to local recurrences and constituting the most common single distant metastatic site. No statistically significant treatment differences were found among the three categories of relapse used (local recurrence, isolated brain recurrences, and other systemic recurrences). years of follow-up, 61% of the patients were alive in the chemotherapy group and 48% were alive in the control group (p=0.050). The 5-year survival rate was 67% in the chemotherapy group and 56% in the control group (p=0.05). Niiranen and colleagues'0 concluded that patients with non-small cell lung cancer of pathologic stage I who undergo radical surgery benefit from adjuvant chemotherapy. They pointed out that the greatest benefit was observed in the group of patients treated with CAP who received their planned six courses of chemotherapy.
DISCUSSION
In our study and the Finnish study, the main compliance problem was associated with chemotherapy-induced nausea. Vomiting was often intractable with the antiemetic agents in use at the time of the two studies. It was particularly difficult to motivate patients to continue treatment after they were informed that their surgery had been successful and no disease remained. Rapp et all' comparing best supportive care to vindesine plus cisplatin and CAP, the vindesine-cisplatin arm was superior to either of the other two arms, suggesting that a vinca-alkaloid-cisplatin combination might be preferable to the standard CAP regimen. This might be particularly advantageous in earlier-stage disease. In addition, new drugs such as vinorelbine (Navelbine), gemcitabine, cpt-11, taxol, and taxotere combined with cisplatin may prove to be even better than available vinca-alkaloid-cisplatin combinations.
The fact that at least one study'o shows a survival benefit with a relatively ineffective regimen (CAP) argues strongly for further studies with new combinations and appropriate supportive care such as the new antiemetics presently available. One such study is expected to begin in Canada sometime in 1994. The Lung Site Group of the National Cancer Institute of Canada will compare vinorelbine plus cisplatin with close observation in stage I non-small cell lung cancer. Other studies using different regimens will undoubtedly begin in other parts of the world and should be encouraged. If we can improve compliance and hopefully improve antineoplastic activity with new combinations, the best hope for survival improvement in the lung cancer population (particularly early stage) is with the Lse of adjuvant treatment. Therefore, testing new adjuvant treatments should be among the main research priorities in the 1990s to try to improve survival in resectable non-small cell lung cancer.
